{"id":4948,"date":"2026-01-16T15:01:57","date_gmt":"2026-01-16T05:01:57","guid":{"rendered":"\/eu-uk\/?p=4948"},"modified":"2026-01-20T15:19:43","modified_gmt":"2026-01-20T05:19:43","slug":"ausbiz-interview-with-john-van-der-wielen-3","status":"publish","type":"post","link":"\/eu-uk\/blog\/2026\/01\/16\/ausbiz-interview-with-john-van-der-wielen-3\/","title":{"rendered":"Ausbiz | Interview with John Van Der\u202fWielen\u202f"},"content":{"rendered":"<p><span data-contrast=\"auto\">Orthocell\u00a0Chairman\u202fJohn Van Der\u202fWielen\u202frecently spoke with\u202fausbiz\u00a0about the\u202fCompany\u2019s\u00a0<\/span><a href=\"https:\/\/cdn-api.markitdigital.com\/apiman-gateway\/ASX\/asx-research\/1.0\/file\/2924-03046622-6A1307305&amp;v=undefined\"><span data-contrast=\"none\">strategic investment in Marine Biomedical<\/span><\/a><span data-contrast=\"auto\">\u00a0and the rationale behind securing global distribution rights to\u202fPearlBone\u2122.\u202f<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">John highlighted the strong clinical and commercial alignment between the two technologies in trauma settings, where surgeons often need to repair bone,\u00a0nerve\u00a0and\u00a0tendon together, as well as the strategic timing of the investment as\u00a0PearlBone\u00a0prepares for FDA submission and leverages\u00a0Orthocell\u2019s\u00a0established international distribution network.<\/span><\/p>\n<p><iframe loading=\"lazy\" title=\"Ausbiz | Interview with Orthocell Chairman John Van Der Wielen\" width=\"1180\" height=\"664\" src=\"https:\/\/www.youtube.com\/embed\/D_-oc-kpeA4?start=35&#038;feature=oembed&#038;enablejsapi=1&#038;origin=https:\/\/orthocell.com&#038;v=D_-oc-kpeA4&#038;t=35s\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell\u00a0Chairman\u202fJohn Van Der\u202fWielen\u202frecently spoke with\u202fausbiz\u00a0about the\u202fCompany\u2019s\u00a0strategic investment in Marine Biomedical\u00a0and the rationale behind securing global distribution rights to\u202fPearlBone\u2122.\u202f\u00a0<\/p>\n","protected":false},"author":2,"featured_media":4754,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4948","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4948"}],"version-history":[{"count":2,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4948\/revisions"}],"predecessor-version":[{"id":4950,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4948\/revisions\/4950"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4754"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4948"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}